Differential effects of direct thrombin inhibitors and antithrombin- dependent anticoagulants on the dynamics of clot formation

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 2, 2007, Pages 97-103

  Young, Guy ^a   Yonekawa, Karyn E ^a   Nakagawa, Peggy A ^a   Blain, Rachelle C ^a   Lovejoy, Amy E ^a   Nugent, Diane J ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Anticoagulation; Direct thrombin inhibitors; Thromboelastography

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; HIRULOG; KAOLIN; THROMBIN INHIBITOR; THROMBOPLASTIN;

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; ELASTICITY; EX VIVO STUDY; HEMATOLOGICAL PARAMETERS; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RIGIDITY; STATISTICAL SIGNIFICANCE; THROMBOELASTOGRAPHY;

ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; DRUG EVALUATION, PRECLINICAL; ELASTICITY; ENOXAPARIN; HEPARIN; HIRUDINS; HUMANS; KINETICS; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; POLYSACCHARIDES; RECOMBINANT PROTEINS; STRESS, MECHANICAL; THROMBELASTOGRAPHY; THROMBIN;

EID: 33846912484     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3280116c4c     Document Type: Article

References (16)

1. Hirsh J. Current anticoagulant therapy - unmet clinical needs. Thromb Res 2003; 15 (Suppl 1):S1-S8.
2. Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004; 38:99-109.
3. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142:952-959.
4. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853-863.
5. Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994; 113:1209-1214.
6. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33:1879-1885.
7. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702.
8. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295:1519-1530.
9. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464-1476.
10. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1833-1840.
11. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867-873.
12. Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis 2001; 12:327-337.
13. Shore-Lesserson L. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function. Semin Cardiothor Vasc Anesth 2005; 9:41-52.
14. Klein SM, Slaughter TF, Vail PT, Ginsberg B, El-Moalem HE, Alexander R, et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth Analg 2000; 91:1091-1095.
15. Gerotziafas GT, Chakroun T, Samama MM, Elalamy I. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thromb Haemost 2004; 92:1296-1302.
16. Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. J Heart Lung Transplant 2006; 25:653-663.